Cyclo (-RGDfK) (Synonyms: Cyclo(-Arg-Gly-Asp-D-Phe-Lys)) |
Katalog-Nr.GC17610 |
Ein Inhibitor des αvβ3-Integrins
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 161552-03-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyclo(-RGDfK) ist ein potenter und selektiver Inhibitor des αvβ3-Integrins mit einer IC50 von 0,94 nM.
Cyclo(-RGDfK) ist ein potenter und selektiver Inhibitor des αvβ3-Integrins mit einer IC50 von 0,94 nM[1]. [(66)Ga]DOTA-E-[c(RGDfK)]2 kann mit hoher radiochemischer Reinheit (>97%), spezifischer Aktivität (36-67GBq/μM), in vitro Stabilität und mäßiger Proteinbindung hergestellt werden. MikroPET-Bildgebung bis zu 24 Stunden nach der Injektion zeigte kontrastierende Tumoren, die auf eine akkumulierte αvβ3-gerichtete Tracer-Aufnahme hinweisen[2].
References:
[1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
[2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
Cas No. | 161552-03-0 | SDF | |
Überlieferungen | Cyclo(-Arg-Gly-Asp-D-Phe-Lys) | ||
Chemical Name | 2-[(2S,5R,8S,11S)-8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid | ||
Canonical SMILES | C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O | ||
Formula | C27H41N9O7 | M.Wt | 603.7 |
Löslichkeit | ≥ 30.185mg/mL in DMSO, ≥ 59.2 mg/mL in Water | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6565 mL | 8.2823 mL | 16.5645 mL |
5 mM | 0.3313 mL | 1.6565 mL | 3.3129 mL |
10 mM | 0.1656 mL | 0.8282 mL | 1.6565 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *